206 related articles for article (PubMed ID: 35000264)
21. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
Arisi MF; Dotan E; Fernandez SV
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
[TBL] [Abstract][Full Text] [Related]
22. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.
Bent A; Raghavan S; Dasari A; Kopetz S
Clin Colorectal Cancer; 2022 Jun; 21(2):89-95. PubMed ID: 35450837
[TBL] [Abstract][Full Text] [Related]
23. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA.
Wei Q; Zhang Y; Gao J; Li J; Li J; Li Y; Zhou J; Lu M; Gong J; Zhang X; Shen L; Sun Y; Chang L; Wang X
Clin Colorectal Cancer; 2019 Sep; 18(3):175-182. PubMed ID: 31227437
[TBL] [Abstract][Full Text] [Related]
25. Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study.
Sui J; Wu X; Wang C; Wang G; Li C; Zhao J; Zhang Y; Xiang J; Xu Y; Nian W; Cao F; Yu G; Lou Z; Hao L; Liu L; Li B; Zhang Z; Cai S; Liu H; Lan P; Zhang W
Clin Epigenetics; 2021 Feb; 13(1):26. PubMed ID: 33536049
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer.
Zou D; Day R; Cocadiz JA; Parackal S; Mitchell W; Black MA; Lawrence B; Fitzgerald S; Print C; Jackson C; Guilford P
Carcinogenesis; 2020 Nov; 41(11):1507-1517. PubMed ID: 32955091
[TBL] [Abstract][Full Text] [Related]
27. Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures.
Gouda MA; Duose DY; Lapin M; Zalles S; Huang HJ; Xi Y; Zheng X; Aldesoky AI; Alhanafy AM; Shehata MA; Wang J; Kopetz S; Meric-Bernstam F; Wistuba II; Luthra R; Janku F
Oncologist; 2023 Apr; 28(4):368-372. PubMed ID: 36200910
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of methylated branched chain amino acid transaminase 1/IKAROS family zinc finger 1 for colorectal cancer.
Xu K; Yu AR; Pan SB; He J
World J Gastroenterol; 2023 Sep; 29(36):5240-5253. PubMed ID: 37901447
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients.
Yang YC; Wang D; Jin L; Yao HW; Zhang JH; Wang J; Zhao XM; Shen CY; Chen W; Wang XL; Shi R; Chen SY; Zhang ZT
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29914973
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
[TBL] [Abstract][Full Text] [Related]
32. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.
Moati E; Blons H; Taly V; Garlan F; Wang-Renault SF; Pietrasz D; Didelot A; Garrigou S; Saint A; Pernot S; Taieb J; Laurent-Puig P; Zaanan A
Int J Cancer; 2020 Aug; 147(4):1185-1189. PubMed ID: 31472013
[TBL] [Abstract][Full Text] [Related]
33. The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer.
Manca P; Corallo S; Busico A; Lonardi S; Corti F; Antoniotti C; Procaccio L; Clavarezza M; Smiroldo V; Tomasello G; Murialdo R; Sartore-Bianchi A; Racca P; Pagani F; Randon G; Martinetti A; Sottotetti E; Palermo F; Perrone F; Tamborini E; Prisciandaro M; Raimondi A; Di Bartolomeo M; Morano F; Pietrantonio F
Clin Cancer Res; 2021 May; 27(9):2505-2514. PubMed ID: 33547199
[TBL] [Abstract][Full Text] [Related]
34. Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.
Nassar FJ; Msheik ZS; Nasr RR; Temraz SN
Clin Epigenetics; 2021 May; 13(1):111. PubMed ID: 34001239
[TBL] [Abstract][Full Text] [Related]
35. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
36. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
Tie J; Cohen JD; Lo SN; Wang Y; Li L; Christie M; Lee M; Wong R; Kosmider S; Skinner I; Wong HL; Lee B; Burge ME; Yip D; Karapetis CS; Price TJ; Tebbutt NC; Haydon AM; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Popoli M; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Int J Cancer; 2021 Feb; 148(4):1014-1026. PubMed ID: 32984952
[TBL] [Abstract][Full Text] [Related]
38. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer.
Luo H; Zhao Q; Wei W; Zheng L; Yi S; Li G; Wang W; Sheng H; Pu H; Mo H; Zuo Z; Liu Z; Li C; Xie C; Zeng Z; Li W; Hao X; Liu Y; Cao S; Liu W; Gibson S; Zhang K; Xu G; Xu RH
Sci Transl Med; 2020 Jan; 12(524):. PubMed ID: 31894106
[TBL] [Abstract][Full Text] [Related]
39. Aberrant circulating tumor DNA methylation and exosomal microRNA biomarkers for early detection of colorectal cancer.
Zhang X; Hou H; Jiang M; Zhang X
Mol Biol Rep; 2023 Mar; 50(3):2743-2750. PubMed ID: 36583782
[TBL] [Abstract][Full Text] [Related]
40. Recurrence risk assessment for stage III colorectal cancer based on five methylation biomarkers in plasma cell-free DNA.
Wang W; Zhu X; Zhang X; Lei C; Zeng Z; Lan X; Cui W; Wang F; Xu S; Zhou J; Wu X; Deng H; Li X; Fan J; Ding Y; Huang Z; Liang L
J Pathol; 2023 Apr; 259(4):376-387. PubMed ID: 36573552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
